Combinatorial therapy of zinc metallochaperones with mutant p53 reactivation and diminished copper binding

Saif Zaman, Xin Yu, Anthony F. Bencivenga, Adam R. Blanden, Yue Liu, Tracy Withers, Bing Na, Alan J. Blayney, John Gilleran, David A Boothman, Stewart N. Loh, S. David Kimball, Darren R. Carpizo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Chemotherapy and radiation are more effective in wild-type (WT) p53 tumors due to p53 activation. This is one rationale for developing drugs that reactivate mutant p53 to synergize with chemotherapy and radiation. Zinc metallochaperones (ZMC) are a new class of mutant p53 reactivators that restore WT structure and function to zinc-deficient p53 mutants. We hypothesized that the thiosemicarbazone, ZMC1, would synergize with chemotherapy and radiation. Surprisingly, this was not found. We explored the mechanism of this and found the reactive oxygen species (ROS) activity of ZMC1 negates the signal on p53 that is generated with chemotherapy and radiation. Wehypothesized that a zinc scaffold generating lessROS would synergize with chemotherapy and radiation. The ROS effect of ZMC1 is generated by its chelation of redox active copper. ZMC1 copper binding (KCu) studies reveal its affinity for copper is approximately 108 greater than Zn2+. We identified an alternative zinc scaffold (nitrilotriacetic acid) and synthesized derivatives to improve cell permeability. These compounds bind zinc in the same range as ZMC1 but bound copper much less avidly (106- to 107-fold lower) and induced less ROS. These compounds were synergistic with chemotherapy and radiation by inducing p53 signaling events on mutant p53. We explored other combinations with ZMC1 based on its mechanism of action and demonstrate that ZMC1 is synergistic with MDM2 antagonists, BCL2 antagonists, and molecules that deplete cellular reducing agents. We have identified an optimal Cu2+:Zn2+ binding ratio to facilitate development of ZMCs as chemotherapy and radiation sensitizers. Although ZMC1 is not synergistic with chemotherapy and radiation, it is synergistic with a number of other targeted agents.

Original languageEnglish (US)
Pages (from-to)1355-1365
Number of pages11
JournalMolecular Cancer Therapeutics
Volume18
Issue number8
DOIs
StatePublished - Jan 1 2019

Fingerprint

Metallochaperones
Zinc
Copper
Drug Therapy
Radiation
Reactive Oxygen Species
Therapeutics
Zinc Compounds
Nitrilotriacetic Acid
Radiation-Sensitizing Agents
Thiosemicarbazones
Reducing Agents
Oxidation-Reduction
Permeability

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zaman, S., Yu, X., Bencivenga, A. F., Blanden, A. R., Liu, Y., Withers, T., ... Carpizo, D. R. (2019). Combinatorial therapy of zinc metallochaperones with mutant p53 reactivation and diminished copper binding. Molecular Cancer Therapeutics, 18(8), 1355-1365. https://doi.org/10.1158/1535-7163.MCT-18-1080

Combinatorial therapy of zinc metallochaperones with mutant p53 reactivation and diminished copper binding. / Zaman, Saif; Yu, Xin; Bencivenga, Anthony F.; Blanden, Adam R.; Liu, Yue; Withers, Tracy; Na, Bing; Blayney, Alan J.; Gilleran, John; Boothman, David A; Loh, Stewart N.; Kimball, S. David; Carpizo, Darren R.

In: Molecular Cancer Therapeutics, Vol. 18, No. 8, 01.01.2019, p. 1355-1365.

Research output: Contribution to journalArticle

Zaman, S, Yu, X, Bencivenga, AF, Blanden, AR, Liu, Y, Withers, T, Na, B, Blayney, AJ, Gilleran, J, Boothman, DA, Loh, SN, Kimball, SD & Carpizo, DR 2019, 'Combinatorial therapy of zinc metallochaperones with mutant p53 reactivation and diminished copper binding', Molecular Cancer Therapeutics, vol. 18, no. 8, pp. 1355-1365. https://doi.org/10.1158/1535-7163.MCT-18-1080
Zaman, Saif ; Yu, Xin ; Bencivenga, Anthony F. ; Blanden, Adam R. ; Liu, Yue ; Withers, Tracy ; Na, Bing ; Blayney, Alan J. ; Gilleran, John ; Boothman, David A ; Loh, Stewart N. ; Kimball, S. David ; Carpizo, Darren R. / Combinatorial therapy of zinc metallochaperones with mutant p53 reactivation and diminished copper binding. In: Molecular Cancer Therapeutics. 2019 ; Vol. 18, No. 8. pp. 1355-1365.
@article{6ecb71d4a5e248b7b33d5bcb48617725,
title = "Combinatorial therapy of zinc metallochaperones with mutant p53 reactivation and diminished copper binding",
abstract = "Chemotherapy and radiation are more effective in wild-type (WT) p53 tumors due to p53 activation. This is one rationale for developing drugs that reactivate mutant p53 to synergize with chemotherapy and radiation. Zinc metallochaperones (ZMC) are a new class of mutant p53 reactivators that restore WT structure and function to zinc-deficient p53 mutants. We hypothesized that the thiosemicarbazone, ZMC1, would synergize with chemotherapy and radiation. Surprisingly, this was not found. We explored the mechanism of this and found the reactive oxygen species (ROS) activity of ZMC1 negates the signal on p53 that is generated with chemotherapy and radiation. Wehypothesized that a zinc scaffold generating lessROS would synergize with chemotherapy and radiation. The ROS effect of ZMC1 is generated by its chelation of redox active copper. ZMC1 copper binding (KCu) studies reveal its affinity for copper is approximately 108 greater than Zn2+. We identified an alternative zinc scaffold (nitrilotriacetic acid) and synthesized derivatives to improve cell permeability. These compounds bind zinc in the same range as ZMC1 but bound copper much less avidly (106- to 107-fold lower) and induced less ROS. These compounds were synergistic with chemotherapy and radiation by inducing p53 signaling events on mutant p53. We explored other combinations with ZMC1 based on its mechanism of action and demonstrate that ZMC1 is synergistic with MDM2 antagonists, BCL2 antagonists, and molecules that deplete cellular reducing agents. We have identified an optimal Cu2+:Zn2+ binding ratio to facilitate development of ZMCs as chemotherapy and radiation sensitizers. Although ZMC1 is not synergistic with chemotherapy and radiation, it is synergistic with a number of other targeted agents.",
author = "Saif Zaman and Xin Yu and Bencivenga, {Anthony F.} and Blanden, {Adam R.} and Yue Liu and Tracy Withers and Bing Na and Blayney, {Alan J.} and John Gilleran and Boothman, {David A} and Loh, {Stewart N.} and Kimball, {S. David} and Carpizo, {Darren R.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-18-1080",
language = "English (US)",
volume = "18",
pages = "1355--1365",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Combinatorial therapy of zinc metallochaperones with mutant p53 reactivation and diminished copper binding

AU - Zaman, Saif

AU - Yu, Xin

AU - Bencivenga, Anthony F.

AU - Blanden, Adam R.

AU - Liu, Yue

AU - Withers, Tracy

AU - Na, Bing

AU - Blayney, Alan J.

AU - Gilleran, John

AU - Boothman, David A

AU - Loh, Stewart N.

AU - Kimball, S. David

AU - Carpizo, Darren R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Chemotherapy and radiation are more effective in wild-type (WT) p53 tumors due to p53 activation. This is one rationale for developing drugs that reactivate mutant p53 to synergize with chemotherapy and radiation. Zinc metallochaperones (ZMC) are a new class of mutant p53 reactivators that restore WT structure and function to zinc-deficient p53 mutants. We hypothesized that the thiosemicarbazone, ZMC1, would synergize with chemotherapy and radiation. Surprisingly, this was not found. We explored the mechanism of this and found the reactive oxygen species (ROS) activity of ZMC1 negates the signal on p53 that is generated with chemotherapy and radiation. Wehypothesized that a zinc scaffold generating lessROS would synergize with chemotherapy and radiation. The ROS effect of ZMC1 is generated by its chelation of redox active copper. ZMC1 copper binding (KCu) studies reveal its affinity for copper is approximately 108 greater than Zn2+. We identified an alternative zinc scaffold (nitrilotriacetic acid) and synthesized derivatives to improve cell permeability. These compounds bind zinc in the same range as ZMC1 but bound copper much less avidly (106- to 107-fold lower) and induced less ROS. These compounds were synergistic with chemotherapy and radiation by inducing p53 signaling events on mutant p53. We explored other combinations with ZMC1 based on its mechanism of action and demonstrate that ZMC1 is synergistic with MDM2 antagonists, BCL2 antagonists, and molecules that deplete cellular reducing agents. We have identified an optimal Cu2+:Zn2+ binding ratio to facilitate development of ZMCs as chemotherapy and radiation sensitizers. Although ZMC1 is not synergistic with chemotherapy and radiation, it is synergistic with a number of other targeted agents.

AB - Chemotherapy and radiation are more effective in wild-type (WT) p53 tumors due to p53 activation. This is one rationale for developing drugs that reactivate mutant p53 to synergize with chemotherapy and radiation. Zinc metallochaperones (ZMC) are a new class of mutant p53 reactivators that restore WT structure and function to zinc-deficient p53 mutants. We hypothesized that the thiosemicarbazone, ZMC1, would synergize with chemotherapy and radiation. Surprisingly, this was not found. We explored the mechanism of this and found the reactive oxygen species (ROS) activity of ZMC1 negates the signal on p53 that is generated with chemotherapy and radiation. Wehypothesized that a zinc scaffold generating lessROS would synergize with chemotherapy and radiation. The ROS effect of ZMC1 is generated by its chelation of redox active copper. ZMC1 copper binding (KCu) studies reveal its affinity for copper is approximately 108 greater than Zn2+. We identified an alternative zinc scaffold (nitrilotriacetic acid) and synthesized derivatives to improve cell permeability. These compounds bind zinc in the same range as ZMC1 but bound copper much less avidly (106- to 107-fold lower) and induced less ROS. These compounds were synergistic with chemotherapy and radiation by inducing p53 signaling events on mutant p53. We explored other combinations with ZMC1 based on its mechanism of action and demonstrate that ZMC1 is synergistic with MDM2 antagonists, BCL2 antagonists, and molecules that deplete cellular reducing agents. We have identified an optimal Cu2+:Zn2+ binding ratio to facilitate development of ZMCs as chemotherapy and radiation sensitizers. Although ZMC1 is not synergistic with chemotherapy and radiation, it is synergistic with a number of other targeted agents.

UR - http://www.scopus.com/inward/record.url?scp=85071048698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071048698&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-18-1080

DO - 10.1158/1535-7163.MCT-18-1080

M3 - Article

C2 - 31196889

AN - SCOPUS:85071048698

VL - 18

SP - 1355

EP - 1365

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 8

ER -